0.45

0.00% +0.00

After Hours: .44 -0.01 -2.22%

Scinai Immunotherapeutics Ltd ADR (SCNI)

Overview News Price History Discussions Forecast Stock Split

Scinai Immunotherapeutics Ltd ADR stock is currently priced at $0.45, with a 24-hour trading volume of 19,082. It has seen a +0.00% increased in the last 24 hours and a +0.47% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.4457 pivot point. If it approaches the $0.4543 resistance level, significant changes may occur.

Previous Close:

$0.45

Open:

$0.4461

24h Volume:

19,082

Market Cap:

$2.62M

Revenue:

Net Income/Loss:

$-9.29M

P/E Ratio:

-0.1484

EPS:

-3.0332

Net Cash Flow:

$-9.42M

1W Performance:

-4.26%

1M Performance:

+0.47%

6M Performance:

-28.57%

1Y Performance:

+0.00%

1D Range:

$0.432

$0.469

52W Range:

$0.4303

$1.37

Scinai Immunotherapeutics Ltd ADR Stock (SCNI) Company Profile

Name

Scinai Immunotherapeutics Ltd ADR

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

972 8 930 2529

Address

Jerusalem BioPark Building, 2nd floor Hadassah Ein Kerem Campus, Jerusalem

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SCNI's Discussions on Twitter

Scinai Immunotherapeutics Ltd ADR Stock (SCNI) Latest News

Scinai Immunotherapeutics Showcases Growth and Innovation - TipRanks.com - TipRanks

TipRanks

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update - Marketscreener.com

Marketscreener.com

Scinai Immunotherapeutics Battles Nasdaq Delisting - TipRanks.com - TipRanks

TipRanks

Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com

Investing.com

Scinai Immunotherapeutics Ltd ADR Stock (SCNI) Financials Data

Scinai Immunotherapeutics Ltd ADR (SCNI) Net Income 2024

SCNI net income (TTM) was -$9.29 million for the quarter ending September 30, 2023, a -4,990% decrease year-over-year.

Scinai Immunotherapeutics Ltd ADR (SCNI) Cash Flow 2024

SCNI recorded a free cash flow (TTM) of -$9.42 million for the quarter ending September 30, 2023, a +31.34% increase year-over-year.

Scinai Immunotherapeutics Ltd ADR (SCNI) Earnings per Share 2024

SCNI earnings per share (TTM) was -$5.20 for the quarter ending September 30, 2023, a -783.00% decline year-over-year.

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.